The ineligible patient: How to treat patients not included in clinical studies

World Journal of Urology

Volumn 32, Issue 1, 2014, Pages 9-18

  Mao, Frances J ^a   Rini, Brian I ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Axitinib; Bevacizumab; Everolimus; Ineligible patients; Metastatic renal cell carcinoma; Pazopanib; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; COMORBIDITY; HEART DISEASE; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; METHODOLOGY; MOLECULARLY TARGETED THERAPY; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COMORBIDITY; ELIGIBILITY DETERMINATION; HEART DISEASES; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893682306     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1042-2     Document Type: Article

References (51)

1. Schlesinger-Raab A, Treiber U, Zaak D, Hölzel D, Engel J (2008) Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 44(16): 2485-2495.
2. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340: c869.
3. Schulz K, Grimes D (2002) Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 359: 781-785.
4. Braunholtz DA, Edwards SJ, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 54(3): 217-224.
5. Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405): 263-270.
6. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD (2008) Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev (3): MR000009. doi: 10. 1002/14651858. MR000009. pub4.
7. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271-2281.
8. Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-216.
9. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13): 2144-2150.
10. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33): 5422-5428.
11. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134.
12. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807): 1931-1939.
13. Motzer R, Bander N, Nanus D (1996) Renal-cell carcinoma. N Engl J Med 335(12): 865-875.
14. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49(5): 798-805.
15. Deng F-M, Melamed J (2012) Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin N Am 39(2): 119-132.
16. Dutcher JP, De Souza P, McDermott D, Figlin Ra, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2): 202-209.
17. Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8): 757-763.
18. Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5): 1272-1280.
19. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1): 127-131.
20. Tannir NM, Plimack E, Ng C, et al (2012) A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. doi: 10. 1016/j. eururo. 2012. 06. 043.
21. Motzer R, Mazumdar M (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540.
22. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3): 454-463.
23. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3): 543-550.
24. Beck J, Procopio G, Bajetta E et al (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22(8): 1812-1823.
25. Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U (2009) Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients with renal insufficiency (RI). J Clin Oncol 27(15 s): suppl; abstr 5108.
26. Josephs D, Hutson T (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108(8): 1279-1283.
27. Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50(4): 472-481.
28. Pfizer (2011) Sutent: highlights of prescribing information. http://labeling. pfizer. com/ShowLabeling. aspx?id=607. Accessed 11 Sep 2012.
29. Macfarlane R, Heng DYC, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK (2012) The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118(2): 365-370.
30. Saitoh H (1981) Distant metastasis of renal adenocarcinoma. Cancer 48(6): 1487-1491.
31. Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA (1997) External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37(4): 753-759.
32. Nieder C (1999) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 85(1): 251-253.
33. Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83(12): 2548-2553.
34. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21): 4958-4965.
35. Gore ME, Hariharan S, Porta C et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3): 501-509.
36. Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19(9): 1613-1618.
37. Di Lorenzo G, Autorino R, Bruni G et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20(9): 1535-1542.
38. Richards CJ, Je Y, Schutz FAB, Heng DYC, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29(25): 3450-3456.
39. Greineder CF, Kohnstamm S, Ky B (2011) Heart failure associated with sunitinib: lessons learned from animal models. Curr Hypertens Rep 13(6): 436-441.
40. Gupta R, Maitland ML (2011) Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 13(6): 430-435.
41. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124.
42. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111.
43. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456.
44. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18): 4256-4265.
45. (2012) National comprehensive cancer network guidelines for kidney cancer. http://www. nccn. org/professionals/physician_gls/pdf/kidney. pdf. Accessed 19 Sep 2012.
46. Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3): 333-339.
47. Calvo E, Ravaud A, Bellmunt J (2012) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. doi: 10. 1016/j. ctrv. 2012. 06. 010.
48. Heng DY, Choueiri TK, Lee J-L et al (2012) A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. J Clin Oncol 30(Suppl 5): abstr 353.
49. Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13): 2137-2143.
50. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068.
51. Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20): 3312-3318.